<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918370</url>
  </required_header>
  <id_info>
    <org_study_id>102015-062</org_study_id>
    <nct_id>NCT02918370</nct_id>
  </id_info>
  <brief_title>Aripiprazole for Bipolar Disorder and Alcohol Use Disorder</brief_title>
  <official_title>Aripiprazole for Bipolar Disorder and Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a 12-week, randomized, double-blind, parallel-group,&#xD;
      placebo-controlled study of aripiprazole in 132 persons with Alcohol Use Disorder (AUD) and&#xD;
      bipolar I or II disorder, currently depressed or mixed phase. Primary Aim will be to assess&#xD;
      change in alcohol use by the Timeline Followback (TLFB) method. Secondary Aim will include&#xD;
      change in alcohol craving using the Penn Alcohol Craving Scale (PACS). Changes in psychiatric&#xD;
      symptoms (mania/hypomania and depression) and predictors of response will be assessed.&#xD;
      Participants with ≥ 1 drinking day at week 12 will be enrolled in a 4-week extension phase&#xD;
      with an upward titration to 30 mg/day for those in the active treatment group. The placebo&#xD;
      group will remain on placebo.&#xD;
&#xD;
      Subjects will be discontinued from the study if any of the following conditions occurs:&#xD;
      change in diagnosis to other than bipolar I or II disorder and AUD, development of active&#xD;
      suicidal or homicidal ideation with plan and intent, worsening in mood symptoms, that in the&#xD;
      opinion of the investigators requires discontinuation, pregnancy, development of severe or&#xD;
      life-threatening medical condition, involuntary psychiatric hospitalization or incarceration,&#xD;
      significant alcohol withdrawal (e.g. delirium tremens) based on clinical judgment (increases&#xD;
      in Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores will initiate a&#xD;
      careful clinical assessment of possible worsening of withdrawal symptoms), or cocaine or&#xD;
      amphetamine-positive urine drug screen during the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timeline Follow Back (TLFB)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Timeline Followback is used to assess recent alcohol use (and if present, other substance use).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Alcoholism</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive ingredient matching the active comparators in appearance.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient men and women age 18-65 years old with bipolar I, II, Not Otherwise&#xD;
             Specified (NOS) disorder, or Schizoaffective Bipolar Type&#xD;
&#xD;
          -  If diagnosed with Bipolar I, Bipolar NOS w/history of mania or Schizoaffective&#xD;
             Disorder Bipolar Type, current mood stabilizer therapy (lithium, valproic acid,&#xD;
             lamotrigine, gabapentin) with stable dose for &gt; 28 days prior to randomization.&#xD;
&#xD;
          -  Baseline Barrett Impulsiveness Scale-11 Score of &gt; 62 (above average impulsivity)&#xD;
&#xD;
          -  Systolic BP &gt; 100 and &lt; 165 and Diastolic BP &gt; 60 and &lt; 105 with no evidence of&#xD;
             orthostatic hypotension&#xD;
&#xD;
          -  Current Diagnosis of Alcohol Use Disorder with at least moderate severity&#xD;
&#xD;
          -  Alcohol use of an average of 15 drinks per 7 days in the past 28 days prior to intake&#xD;
             for men, and an average of 8 drinks per 7 day period in the past 28 days prior to&#xD;
             intake for women&#xD;
&#xD;
          -  Current mood stabilizer therapy with stable dose for &gt; 28 days&#xD;
&#xD;
          -  Fluent in English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline Hamilton Rating Scale for Depression (HRSD) or Young Mania Rating Scale&#xD;
             (YMRS) scores &gt; 35&#xD;
&#xD;
          -  Mood disorders other than bipolar I, II, NOS or schizoaffective disorder bipolar type&#xD;
             (e.g. cyclothymic disorders, schizophrenia, schizoaffective disorder depressive type,&#xD;
             or unipolar depression based on the SCID), other disorders, e.g. anxiety disorders,&#xD;
             will be allowed.&#xD;
&#xD;
          -  Current diagnosis of amphetamine or cocaine use disorder or a cocaine or amphetamine&#xD;
             positive baseline urine sample.&#xD;
&#xD;
          -  Evidence of clinically significant alcohol withdrawal symptoms&#xD;
&#xD;
          -  Current treatment with an atypical antipsychotic&#xD;
&#xD;
          -  Current treatment with naltrexone, acamprosate, disulfiram, or topiramate in the last&#xD;
             28 days&#xD;
&#xD;
          -  Prior treatment with Aripiprazole within the last year or lifetime history of&#xD;
             intolerable side effects to Aripiprazole&#xD;
&#xD;
          -  Vulnerable populations (e.g. pregnant, nursing, cognitively impaired, incarcerated.)&#xD;
&#xD;
          -  Evidence of clinically significant alcohol withdrawal symptoms defined as a CIWA-Ar&#xD;
             score of ≥ 10.&#xD;
&#xD;
          -  High risk for suicide&#xD;
&#xD;
          -  Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) &gt; 3 times upper&#xD;
             limit of normal&#xD;
&#xD;
          -  Current use of Cytochrome P450 3A4 inducing medication (e.g. carbamazepine, rifabutin,&#xD;
             rifampin, ritonavir).&#xD;
&#xD;
          -  Use of other substances (besides cocaine/amphetamine) is allowed if the use disorder&#xD;
             is no greater than moderate severity and alcohol is the self-identified substance of&#xD;
             choice.&#xD;
&#xD;
          -  History of neuroleptic malignant syndrome or tardive dyskinesia.&#xD;
&#xD;
        More specific inclusion and exclusion criteria will be discussed with participant at&#xD;
        baseline assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shailesh Jaiswal</last_name>
    <phone>214-645-6963</phone>
    <email>shailesh.jaiswal@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maisha Razzaque</last_name>
    <phone>214-645-6964</phone>
    <email>maisha.razzaque@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shailesh Jaiswal</last_name>
      <phone>2146456963</phone>
      <email>shailesh.jaiswal@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Traci Holmes</last_name>
      <phone>2146456959</phone>
      <email>traci.holmes@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>E. Sherwood Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Sherwood Brown, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Alcohol Use Disorder</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Mood</keyword>
  <keyword>Alcohol Craving</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

